813 related articles for article (PubMed ID: 27989218)
1. The Safety of available immunotherapy for the treatment of glioblastoma.
Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
[TBL] [Abstract][Full Text] [Related]
2. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
4. Advances in Immunotherapy for Glioblastoma Multiforme.
Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.
Gedeon PC; Champion CD; Rhodin KE; Woroniecka K; Kemeny HR; Bramall AN; Bernstock JD; Choi BD; Sampson JH
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1147-1158. PubMed ID: 32862726
[TBL] [Abstract][Full Text] [Related]
6. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
7. Current vaccine trials in glioblastoma: a review.
Xu LW; Chow KK; Lim M; Li G
J Immunol Res; 2014; 2014():796856. PubMed ID: 24804271
[TBL] [Abstract][Full Text] [Related]
8. Promising vaccines for treating glioblastoma.
Swartz AM; Shen SH; Salgado MA; Congdon KL; Sanchez-Perez L
Expert Opin Biol Ther; 2018 Nov; 18(11):1159-1170. PubMed ID: 30281978
[TBL] [Abstract][Full Text] [Related]
9. Current challenges in designing GBM trials for immunotherapy.
Weathers SP; Gilbert MR
J Neurooncol; 2015 Jul; 123(3):331-7. PubMed ID: 25577401
[TBL] [Abstract][Full Text] [Related]
10. Developing immunotherapeutic strategies to target brain tumors.
Lieberman NA; Moyes KW; Crane CA
Expert Rev Anticancer Ther; 2016 Jul; 16(7):775-88. PubMed ID: 27253692
[TBL] [Abstract][Full Text] [Related]
11. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
[TBL] [Abstract][Full Text] [Related]
12. Prospects of immune checkpoint modulators in the treatment of glioblastoma.
Preusser M; Lim M; Hafler DA; Reardon DA; Sampson JH
Nat Rev Neurol; 2015 Sep; 11(9):504-14. PubMed ID: 26260659
[TBL] [Abstract][Full Text] [Related]
13. Current Immunotherapies for Glioblastoma Multiforme.
Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
Front Immunol; 2020; 11():603911. PubMed ID: 33767690
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma.
Yeo AT; Charest A
J Cell Biochem; 2017 Sep; 118(9):2516-2527. PubMed ID: 28230277
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma stem cells and stem cell-targeting immunotherapies.
Esparza R; Azad TD; Feroze AH; Mitra SS; Cheshier SH
J Neurooncol; 2015 Jul; 123(3):449-57. PubMed ID: 25682090
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
Ferguson SD; Srinivasan VM; Ghali MG; Heimberger AB
Immunotherapy; 2016; 8(4):413-23. PubMed ID: 26973123
[TBL] [Abstract][Full Text] [Related]
17. New perspectives in glioma immunotherapy.
Daga A; Bottino C; Castriconi R; Gangemi R; Ferrini S
Curr Pharm Des; 2011; 17(23):2439-67. PubMed ID: 21827420
[TBL] [Abstract][Full Text] [Related]
18. Immune and viral therapies for malignant primary brain tumors.
Gardeck AM; Sheehan J; Low WC
Expert Opin Biol Ther; 2017 Apr; 17(4):457-474. PubMed ID: 28274139
[TBL] [Abstract][Full Text] [Related]
19. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
Swartz AM; Li QJ; Sampson JH
Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
[TBL] [Abstract][Full Text] [Related]
20. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
Londhe VY; Date V
Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
